Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in January as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock decreased 1.48% or $0.52 during the last trading session, reaching $34.5. About 5,972 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since January 23, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6
Analysts expect Spectrum Brands Holdings, Inc. (NYSE:SPB) to report $0.47 EPS on February, 8.They anticipate $3.45 EPS change or 115.77% from last quarter’s $-2.98 EPS. SPB’s profit would be $25.11M giving it 28.11 P/E if the $0.47 EPS is correct. After having $0.79 EPS previously, Spectrum Brands Holdings, Inc.’s analysts see -40.51% EPS growth. The stock decreased 0.96% or $0.51 during the last trading session, reaching $52.84. About 339,552 shares traded. Spectrum Brands Holdings, Inc. (NYSE:SPB) has declined 55.94% since January 23, 2018 and is downtrending. It has underperformed by 55.94% the S&P500. Some Historical SPB News: 22/03/2018 – Baldwin® Hardware, a Leading Brand of the Hardware & Home Improvement Division of Spectrum Brands, Officially Launches Hollywo; 26/04/2018 – Spectrum Brands 2Q Adj EPS 56c; 26/04/2018 – Spectrum Brands 2Q Adjusted EBITDA $115.6M; 26/04/2018 – SPECTRUM BRANDS HOLDINGS INC – FY 18 CAPITAL EXPENDITURES ARE EXPECTED TO BE BETWEEN $110 MILLION-$120 MILLION; 26/04/2018 – SPECTRUM BRANDS HOLDINGS INC – WILL ORGANIZE GLOBALLY AROUND TWO DIVISIONS FOCUSED ON CONSUMER PRODUCTS AND HOME IMPROVEMENT; 29/05/2018 – Shining New Light on Aquarium Interactivity; 26/04/2018 – Spectrum Brands Names David Maura CEO; 26/04/2018 – Spectrum Brands to Organize Globally Around 2 Divisions Focused on Consumer Products and Home Improvement; 26/04/2018 – SPECTRUM BRANDS HOLDINGS INC – HARDWARE & HOME IMPROVEMENT DIVISION WILL BE COMPRISED OF SECURITY, PLUMBING AND BUILDERS’ HARDWARE BUSINESSES; 29/03/2018 – ENERGIZER HOLDINGS, INC. AND SPECTRUM BRANDS HOLDINGS ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR THE ACQUISITION OF SPECTRUM BRANDS’ BATTERY AND PORTABLE LIGHTING PRODUCTS
Spectrum Brands Holdings, Inc. manufactures, markets, and/or distributes consumer products worldwide. The company has market cap of $2.82 billion. It operates through five divisions: Global Batteries & Appliances, Hardware & Home Improvement, Global Pet Supplies, Home and Garden, and Global Auto Care. It has a 2.55 P/E ratio. The firm offers batteries; battery-powered portable lighting products; small kitchen and home appliances; personal care products; hinges; security, garage door, and window hardware products; floor protection products; residential lockset and door hardware products; commercial door, lock, and hardware products; and plumbing products.
More notable recent Spectrum Brands Holdings, Inc. (NYSE:SPB) news were published by: Seekingalpha.com which released: “BAML sees turnaround for Spectrum Brands – Seeking Alpha” on January 18, 2019, also Investorplace.com with their article: “10 Consumer Stocks to Buy for Income – Investorplace.com” published on January 22, 2019, Globenewswire.com published: “Report: Exploring Fundamental Drivers Behind Spectrum Brands, Amgen, MSCI, Diamondback Energy, Centene, and Paramount Group â€” New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on January 07, 2019. More interesting news about Spectrum Brands Holdings, Inc. (NYSE:SPB) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For January 18, 2019 – Benzinga” published on January 18, 2019 as well as Gurufocus.com‘s news article titled: “GloFish® Brand of Spectrum Brands Pet LLC Announces Electric Green® Long-Fin Barbs – GuruFocus.com” with publication date: January 15, 2019.
Among 5 analysts covering Spectrum Brands Holdings (NYSE:SPB), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Spectrum Brands Holdings had 8 analyst reports since July 31, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of SPB in report on Tuesday, November 20 with “Outperform” rating. As per Monday, November 19, the company rating was downgraded by Oppenheimer. Bank of America maintained the stock with “Neutral” rating in Thursday, October 4 report. Wells Fargo maintained Spectrum Brands Holdings, Inc. (NYSE:SPB) rating on Wednesday, October 17. Wells Fargo has “Market Perform” rating and $75 target. The rating was upgraded by Bank of America on Friday, January 18 to “Buy”. Wells Fargo maintained the stock with “Market Perform” rating in Tuesday, November 20 report. The firm has “Market Perform” rating by Raymond James given on Tuesday, November 20. The stock of Spectrum Brands Holdings, Inc. (NYSE:SPB) has “Outperform” rating given on Tuesday, July 31 by BMO Capital Markets.
Investors sentiment decreased to 0.03 in Q3 2018. Its down 0.61, from 0.64 in 2018Q2. It is negative, as 148 investors sold Spectrum Brands Holdings, Inc. shares while 1 reduced holdings. 2 funds opened positions while 3 raised stakes. 1.20 million shares or 95.70% less from 27.87 million shares in 2018Q2 were reported. Cibc Ww Corporation, New York-based fund reported 21,317 shares. Dynamo Internacional Gestao De Recursos Ltda invested in 363,354 shares. Ancora Advisors Limited Liability Com invested in 171 shares. Michigan-based Schwartz Invest Counsel Inc has invested 0.42% in Spectrum Brands Holdings, Inc. (NYSE:SPB). Great Lakes Advisors Ltd Liability Company holds 0.06% of its portfolio in Spectrum Brands Holdings, Inc. (NYSE:SPB) for 30,017 shares. Moreover, Eagle Asset has 0.01% invested in Spectrum Brands Holdings, Inc. (NYSE:SPB) for 15,471 shares. Check Capital Ca reported 2.26% of its portfolio in Spectrum Brands Holdings, Inc. (NYSE:SPB). Macquarie Grp Limited has invested 0% in Spectrum Brands Holdings, Inc. (NYSE:SPB). Harvey Prns Ltd Liability Com invested 5.77% of its portfolio in Spectrum Brands Holdings, Inc. (NYSE:SPB).
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Continues US Expansion with Addition of New York City Corporate Office and Addition of Management – Nasdaq” on January 03, 2019, also Nasdaq.com with their article: “ASML reports EUR 10.9 billion net sales and EUR 2.6 billion net income in 2018 – Nasdaq” published on January 23, 2019, Nasdaq.com published: “InPlay Oil Corp. Provides Operations Update and 2019 Capital Budget – NASDAQ.com – Nasdaq” on January 22, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Nidec Announces Financial Results for Fiscal Third Quarter and Nine Months Ended December 31, 2018 – Nasdaq” published on January 23, 2019 as well as Nasdaq.com‘s news article titled: “RESTATEMENT OF 2018 ACCORDING TO IFRS ON LEASES – Nasdaq” with publication date: January 18, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $885.34 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.